NCT04747002View on ClinicalTrials.gov

"Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine Dainippon Sumitomo Phama(DSP)-7888 for Acute Myeloid Leukemia Patients."

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 12, 2020

Primary Completion Date

March 31, 2024

Study Completion Date

April 30, 2024

Conditions
Acute Myeloid Leukemia in Remission
Interventions
DRUG

DSP-7888

Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides

Trial Locations (1)

565-0871

RECRUITING

Osaka University, Suita

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

Osaka University

OTHER

NCT04747002 - "Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine Dainippon Sumitomo Phama(DSP)-7888 for Acute Myeloid Leukemia Patients." | Biotech Hunter | Biotech Hunter